Although Cerulean Pharma Inc.'s farthest-along trial with nanoparticle-based, camptothecin-loaded CRLX101 missed its endpoint in a Phase IIb trial against advanced non-small-cell lung cancer (NSCLC), a handful of other studies are ongoing and all have "a very strong biological rationale underpinning" them, said Oliver Fetzer, president and CEO of the Cambridge, Mass.-based firm.